Technical advances in ultrasound, multi-detector computed tomography (MDCT) and magnetic resonance imaging (MRI) have increased our ability to detect small-sized hepatic lesions and low-contrast lesions, which would have escaped detection some years ago [ 1, 2].
Based on a three group study with three repeated measures, ability to detect small to medium effect size differences (Cohen's f = 0.25, Cohen's d = 0.5), and an alpha of 0.05, 80% power will be achieved with a total sample size of 108.
The relatively small sample size limits our ability to detect small to medium effects with statistical precision.
An important limitation of our study is the relatively small sample size, which limits our ability to detect small, but potentially clinically meaningful, differences between study conditions.
The major limitation is our small sample size which limited our ability to detect small, yet meaningful, differences pre- and post-intervention.
We tested the sensitivity of our results to changes in the sampled size and in our ability to detect small changes in antibody levels.
Given that only a subset of the total RIL population was used for this study, the ability to detect small effect QTL was likely to be limited as population size has been demonstrated to limit the sensitivity of QTL detection.
The sample size of 40 patients limits our ability to detect small differences in the sensitivity of the two radiopharmaceuticals.
Limitations of our study include the relative small sample sizes for young adults, which may limit our ability to detect small changes.
In addition, the sample size, particularly of invasive disease cases, limited the ability to detect small statistical differences between the 2 groups.
The size of the sample was relatively small, which might limit the ability to detect small scale effects.
